DelveInsight's "VITRAKVI Market Size, Forecast, and Market Insight Report" highlights the details around VITRAKVI, a TRK, ...
As biomarker testing and the demand for tumor-agnostic therapies rise, ROZLYTREK can potentially target a specialized yet valuable market segment. While competition from other TRK inhibitors ...
VITRAKVI has strong market potential as a first-in-class TRK inhibitor for patients with NTRK gene fusion-positive cancers, regardless of tumor type. The growing adoption of precision oncology ...
12 Three individuals had sustained fractures of the upper and lower limbs. However, unlike SCN9A and NTRK1 CIP, patients with PRDM12 mutations could experience non-global pain insensitivity. In one ...
No pathogenic alteration was detected in the germline, but there were five clinically significant somatic variations, namely, PEAR1-NTRK1 fusion, decreased PTEN copy number, and increased MB21D2, ...
Comparison of PREMM5 and PREMMplus Risk Assessment Models to Identify Lynch Syndrome Chondrosarcomas are rare cancers of cartilage with limited systemic therapy options. To identify potential ...
Background: The exact mechanisms of PD are unclear, but Parkin-mediated mitophagy dysfunction is believed to play a key role. We investigated whether blood levels of Parkin and other biomarkers are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback